Starpharma Receives a R&D tax Incentive Refund of $4.9 Million

  • Dec 16, 2019 AEDT
  • Team Kalkine

Starpharma Holdings Limited (ASX: SPL) has received a $4.9 million R&D tax incentive refund related to the cost of research and development during FY19. As per the company, the refund will strengthen the company’s cash position.

For the quarter ended 30 September 2019, the company had a cash balance of $36.8 million, which did not include this receipt.

This refund will allow the company to direct additional resources towards developing its high-value DEP® oncology assets in parallel.

At AEDT 01:18 PM, the stock was trading at 1.305, up by 2.35% from its previous close.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK